Anticoagulant monitoring techniques in a heparin-induced thrombocytopenia patient undergoing cardiopulmonary bypass using bivalirudin anticoagulant

Journal of Extra-Corporeal Technology

Volumn 36, Issue 4, 2004, Pages 371-374

  Baker, Trace ^a   Chan, Richard ^a,c   Hill, Fredrick ^b  

^a NORTH SHORE UNIVERSITY HOSPITAL   (United States)

^b NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^c LONG ISLAND UNIVERSITY   (United States)

Author keywords

Bivalirudin; Cardiopulmonary bypass (CPB); Heparin induced thrombocytopenia (HIT); High dose thrombin time (HiTT)

Indexed keywords

HEPARIN; HIRULOG; INFUSORIAL EARTH;

AGED; ANAMNESIS; AORTA VALVE REGURGITATION; ARTICLE; BLOOD CLOTTING TIME; CARDIOPULMONARY BYPASS; CASE REPORT; CONGESTIVE HEART FAILURE; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG MONITORING; DYSPNEA; ECHOCARDIOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; GOUT; HEART ATRIUM FIBRILLATION; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; MALE; MITRAL VALVE PROLAPSE; MITRAL VALVE REGURGITATION; POSTOPERATIVE HEMORRHAGE; PREOPERATIVE EVALUATION; PULMONARY HYPERTENSION; THROMBIN TIME; THROMBOCYTE COUNT; TRICUSPID VALVE REGURGITATION;

EID: 11444259040     PISSN: 00221058     EISSN: 29698960     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Campbell KR, Mahaffey KW, Lewis BE, et al. Bivalirudin in patients with heparin-induced thrombocytopenia undergoing percutaneous coronary intervention. J Invas Cardiol. 2000;12(Suppl F):14F-9F.
2. Fabris F, Ahmad S, Cella G, Jeske WP, Walenga JM, Fareed J. Pathophysiology of heparin-induced thrombocytopenia: clinical and diagnostic implications - a review. Arch Pathol Lab Med. 2000;124:1657-66.
3. Follis F, Schmidt CA. Cardiopulmonary bypass in patients with heparin-induced thrombocytopenia and thrombosis. Ann Thorac Surg. 2000;70:2173-80.
4. Lui HK. Dosage, pharmacological effects and clinical outcomes for bivalirudin in percutaneous coronary intervention. J Invas Cardiol. 2000;12(Suppl F):41F-52F.
5. Bates SM, Weitz JI. The mechanism of action of thrombin inhibitors. J Invas Cardiol. 2000;12(Suppl F):27F-32F.
6. Davis Z, Anderson R, Short D, Garber D, Valgiusti A. Favorable outcome with bivalirudin anticoagulation during cardiopulmonary bypass. Ann Thorac Surg. 2003;75:264-5.
7. Koster A, Chew D, Grundel M, Bauer M, Kuppe H, Spiess B. Bivalirudin monitored with the ecarin clotting time for anticoagulation during cardiopulmonary bypass. Anesth Analg. 2003;96:383-6.
8. de Jong MA. High dose thrombin time versus the activated clotting time during cardiopulmonary bypass. J NeSECC. 1998;23:10-3.
9. Shore-Lesserson L, Manspeizer HE, Bolastig M, Harrington D, Vela-Cantos F, DePerio M. Anticoagulation for cardiac surgery in patients receiving preoperative heparin: use of the high-dose thrombin time. Anesth Analg. 2000;90:813-8.
10. Shore-Lesserson L, Gravlee GP. Anticoagulation for cardiopulmonary bypass. In: Gravlee GP. Davis RF, Kurusz M, Utley JR, eds. Cardiopulmonary Bypass: Principles and Practice. Philadelphia: Lippincott Williams and Wilkins; 2000:435-72.